JP2018529742A5 - - Google Patents

Download PDF

Info

Publication number
JP2018529742A5
JP2018529742A5 JP2018517399A JP2018517399A JP2018529742A5 JP 2018529742 A5 JP2018529742 A5 JP 2018529742A5 JP 2018517399 A JP2018517399 A JP 2018517399A JP 2018517399 A JP2018517399 A JP 2018517399A JP 2018529742 A5 JP2018529742 A5 JP 2018529742A5
Authority
JP
Japan
Prior art keywords
ezh2 inhibitor
dose
administered
ezh2
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018517399A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529742A (ja
JP7045985B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/055554 external-priority patent/WO2017062495A2/en
Publication of JP2018529742A publication Critical patent/JP2018529742A/ja
Publication of JP2018529742A5 publication Critical patent/JP2018529742A5/ja
Application granted granted Critical
Publication of JP7045985B2 publication Critical patent/JP7045985B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018517399A 2015-10-06 2016-10-05 Ezh2阻害剤を用いた髄芽腫の処置方法 Expired - Fee Related JP7045985B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562238074P 2015-10-06 2015-10-06
US62/238,074 2015-10-06
US201662299312P 2016-02-24 2016-02-24
US62/299,312 2016-02-24
PCT/US2016/055554 WO2017062495A2 (en) 2015-10-06 2016-10-05 Method of treating medulloblastoma with an ezh2 inhibitor

Publications (3)

Publication Number Publication Date
JP2018529742A JP2018529742A (ja) 2018-10-11
JP2018529742A5 true JP2018529742A5 (enExample) 2019-11-07
JP7045985B2 JP7045985B2 (ja) 2022-04-01

Family

ID=58488487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018517399A Expired - Fee Related JP7045985B2 (ja) 2015-10-06 2016-10-05 Ezh2阻害剤を用いた髄芽腫の処置方法

Country Status (12)

Country Link
US (2) US20190083504A1 (enExample)
EP (2) EP4309738A3 (enExample)
JP (1) JP7045985B2 (enExample)
KR (1) KR20180058829A (enExample)
CN (1) CN108699046A (enExample)
AU (3) AU2016333982A1 (enExample)
CA (1) CA3000983A1 (enExample)
EA (1) EA201890878A1 (enExample)
IL (2) IL258510A (enExample)
MX (1) MX394355B (enExample)
SG (1) SG10201909413SA (enExample)
WO (1) WO2017062495A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2887243C (en) 2012-10-15 2024-04-09 Epizyme, Inc. Methods of treating cancer
MX2018002344A (es) 2015-08-24 2018-07-06 Epizyme Inc Metodo para tratar el cancer.
EP3407978A4 (en) 2016-01-29 2020-01-15 Epizyme Inc POLYTHERAPY FOR THE TREATMENT OF CANCER
JP7121660B2 (ja) 2016-06-01 2022-08-18 エピザイム,インコーポレイティド 癌を処置するためのezh2阻害剤の使用
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
MA49651A (fr) 2017-07-19 2021-04-28 Childrens Medical Center Compositions et procédés pour traiter des maladies associées à un défaut d'empreinte
CA3074720A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. Combination therapy for treating cancer
WO2020247130A1 (en) * 2019-06-03 2020-12-10 Icahn School Of Medicine At Mount Sinai Compounds and methods for inhibiting cancers via rest inhibition
CN111905102A (zh) * 2020-09-04 2020-11-10 福建医科大学附属第一医院 Ezh2抑制剂在治疗胶质瘤中的应用
KR102821233B1 (ko) 2022-02-10 2025-06-17 서울대학교병원 Hsp70을 표적으로 하는 수모세포종 치료 및 전이 억제 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4236945A (en) * 1978-11-27 1980-12-02 Allegheny Ludlum Steel Corporation Phosphorus-iron powder and method of producing soft magnetic material therefrom
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JP5864546B2 (ja) * 2010-05-07 2016-02-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC インダゾール
EA023788B1 (ru) 2010-05-07 2016-07-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Производные индола и фармацевтические композиции на их основе
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
WO2013120104A2 (en) 2012-02-10 2013-08-15 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EP2953941B1 (en) 2013-02-11 2017-04-05 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CA2887243C (en) * 2012-10-15 2024-04-09 Epizyme, Inc. Methods of treating cancer
KR20210117347A (ko) * 2013-12-06 2021-09-28 에피자임, 인코포레이티드 암 치료를 위한 병용 요법
US20190070188A1 (en) * 2015-11-06 2019-03-07 Epizyme, Inc. Pediatric dosing for treatment of cancer with an ezh2 inhibitor

Similar Documents

Publication Publication Date Title
JP2018529742A5 (enExample)
JP2017518334A5 (enExample)
JP2018021046A5 (enExample)
MX2020014000A (es) Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas.
JP2017531033A5 (enExample)
RU2018114447A (ru) Введение дейтерированных усилителей cftr
JP2015510916A5 (enExample)
JP2016512531A5 (enExample)
JP2018534348A5 (enExample)
JP2016534142A5 (enExample)
CN110036005A (zh) 酰胺衍生物及其在药物中的应用
JP2018162255A5 (enExample)
JP2015512406A5 (enExample)
RU2017114352A (ru) АНТАГОНИСТЫ ИНТЕГРИНА ανβ6
JP2015511609A5 (enExample)
JP2016511753A5 (enExample)
JP2016510326A5 (enExample)
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
JP2017222722A5 (enExample)
JP2016512817A5 (enExample)
JP2016199578A5 (enExample)
JP2018502898A5 (enExample)
PH12019502651A1 (en) Use of vibegron to treat overactive bladder
JP2016530238A5 (enExample)
JP2018531273A5 (enExample)